Categories: Life Science | Format :
MARKET DEFINTION
Psychedelics, are a class of psychoactive chemicals that affect perception, emotion, and cognitive processes.. All of the senses are affected by psychedelics, which change a person's thinking, perception of time, and emotions. They may also cause someone to have hallucinations, in which they perceive or hear distorted or unreal objects. The Psilocybin can directly obtained form mushrooms. There are more than 180 different types of psilocybin-containing mushrooms that can produce psychedelic and hallucinatory effects when ingested. Body processes turn psilocybin into psilocin, which is the substance that causes the psychedelic effects.
MARKET DYNAMICS
Many studies and research were taken place, confirming the positive effects of Psilocybin on depression and anxiety. The rising prevalence of depression and anxiety is one of the factors that is fueling market growth. According to the WHO, 5% of individuals worldwide are thought to experience depression. The largest cause of disability in the world today is depression, which also contributes to the overall burden of sickness on the planet. However, the chances of addiction along with the presence of substitute products are anticipated to hamper the market. However, continuous research and development activities along with growing awareness of mental health are projected to create lucrative opportunities in the near future.
REPORT SCOPE
The report titled “Global Psilocybin Assisted Therapy Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Psilocybin Assisted Therapy market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Psilocybin Assisted Therapy market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help assist CXOs in making critical business decisions effectively. The global Psilocybin Assisted Therapy Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.
GEOGRAPHICAL OVERVIEW
The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations throughout the world, as well as the present trend and possibilities that exist in these regions.
MARKET SEGMENTATION
The Global Psilocybin Assisted Therapy Market is segmented based on Psilocybin Source Type, Indication, End-users, and region. Based on Psilocybin Source Type, the market has been segmented into Natural, and Synthetic whereas based on Indication, the market comprises Anxiety & Depression, Addictions, Psychiatric Disorders, Post Traumatic Stress, and Others. Based on End-users, the market has been segmented into Hospitals & Specialty Clinics, Trauma and Rehabilitation Centers, and Academic and Research Institutes.
COMPETITION LANDSCAPE
The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Psilocybin Assisted Therapy market players. The report covers industry activities including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Psilocybin Assisted Therapy market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Psilocybin Assisted Therapy market emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Psilocybin Assisted Therapy industry in the past three years.
Key players in the Global Psilocybin Assisted Therapy Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:
COVID-19 IMPACT ANALYSIS ON THE GLOBAL PSILOCYBIN ASSISTED THERAPY MARKET
The COVID-19 pandemic is still a very personal, individual experience that is also an once-in-a-lifetime worldwide phenomena with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities, and also had a negative impact on global economic development in 2020 unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce is expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.
In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market thereby, providing accurate and trustworthy forecasts.
Report Attribute/Metric |
Details |
Market Size |
In USD Million |
CAGR |
In % (2022-2028) |
Base Year |
2021 |
Forecast Period |
2022 – 2028 |
Historical Data |
2017 to 2021 |
Forecast Unit |
Value (US$ Mn) |
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors and Trends |
Geographies Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
Key Players Analyzed |
MindMed, Compass Pathways, ATAI Life Sciences, Field Trip, Eleusis, Numinus Wellness Inc., Mindbloom, Freedom Biosciences, Natural MedTech, The Enosis Therapeutics, Clairvoyant Therapeutics, Woke Pharmaceuticals, and Other Prominent Players |
Customization & Pricing |
Available on Request (10% Customization is Free) |
RESEARCH PROGRAM DESIGN
KEY QUESTIONS ANSWERED
REASONS FOR BUYING THIS REPORT:
Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical End-users
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Psilocybin Source Type Trends
3.2.2. Indication Trends
3.2.3. End-users Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Psilocybin Assisted Therapy Market
3.6. COVID-19 Impact Assessment in Psilocybin Assisted Therapy Market
3.6.1. Impact Assessment on Global Psilocybin Assisted Therapy Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape
Chapter 4. Global Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
4.1. Global Psilocybin Assisted Therapy Market Share, By Psilocybin Source Type, 2017 - 2028 (USD Million)
4.1.1. Natural
4.1.2. Synthetic
Chapter 5. Global Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
5.1. Global Psilocybin Assisted Therapy Market Share, By Indication, 2017 - 2028 (USD Million)
5.1.1. Anxiety & Depression
5.1.2. Addictions
5.1.3. Psychiatric Disorders
5.1.4. Post-Traumatic Stress
5.1.5. Others
Chapter 6. Global Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
6.1. Global Psilocybin Assisted Therapy Market Share, By End-users, 2017 - 2028 (USD Million)
6.1.1. Hospitals & Specialty Clinics
6.1.2. Trauma and Rehabilitation Centers
6.1.3. Academic and Research Institutes
Chapter 7. North America Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
7.1. North America Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
7.1.1. Market Indication and projections, 2017 - 2028 (USD Million)
7.1.2. North America Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
7.1.3. North America Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
7.1.4. North America Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
7.2. North America Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
7.2.1. U.S. Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
7.2.1.1. U.S. Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
7.2.1.2. U.S. Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
7.2.1.3. U.S. Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
7.2.2. Canada Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
7.2.2.1. Canada Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
7.2.2.2. Canada Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
7.2.2.3. Canada Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
7.2.3. Mexico Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
7.2.3.1. Mexico Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
7.2.3.2. Mexico Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
7.2.3.3. Mexico Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
Chapter 8. Europe Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
8.1. Europe Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.1.1. Market Indication and projections, 2017 - 2028 (USD Million)
8.1.2. Europe Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.1.3. Europe Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.1.4. Europe Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2. Europe Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
8.2.1. Germany Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.1.1. Germany Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.1.2. Germany Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.1.3. Germany Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2.2. France Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.2.1. France Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.2.2. France Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.2.3. France Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2.3. UK Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.3.1. UK Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.3.2. UK Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.3.3. UK Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2.4. Italy Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.4.1. Italy Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.4.2. Italy Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.4.3. Italy Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2.5. Spain Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.5.1. Spain Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.5.2. Spain Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.5.3. Spain Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2.6. NORDIC Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.6.1. NORDIC Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.6.2. NORDIC Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.6.3. NORDIC Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2.7. Russia and CIS Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.7.1. Russia and CIS Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.7.2. Russia and CIS Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.7.3. Russia and CIS Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
8.2.8. Rest of Europe Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
8.2.8.1. Rest of Europe Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
8.2.8.2. Rest of Europe Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
8.2.8.3. Rest of Europe Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
Chapter 9. Asia Pacific Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. Asia Pacific Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market Indication and projections, 2017 - 2028 (USD Million)
9.1.2. Asia Pacific Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.1.3. Asia Pacific Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.1.4. Asia Pacific Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
9.2. Asia Pacific Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. India Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. India Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.2.1.2. India Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.1.3. India Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
9.2.2. China Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. China Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.2.2.2. China Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.2.3. China Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
9.2.3. Japan Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. Japan Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.2.3.2. Japan Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.3.3. Japan Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
9.2.4. ASEAN Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.2.4.1. ASEAN Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.2.4.2. ASEAN Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.4.3. ASEAN Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
9.2.5. South Korea Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.2.5.1. South Korea Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.2.5.2. South Korea Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.5.3. South Korea Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
9.2.6. Australia Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.2.6.1. Australia Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.2.6.2. Australia Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.6.3. Australia Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
9.2.7. Rest of Asia Pacific Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
9.2.7.1. Rest of Asia Pacific Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
9.2.7.2. Rest of Asia Pacific Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
9.2.7.3. Rest of Asia Pacific Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
Chapter 10. South America Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. South America Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market Indication and projections, 2017 - 2028 (USD Million)
10.1.2. South America Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
10.1.3. South America Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
10.1.4. South America Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
10.2. South America Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. Brazil Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. Brazil Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
10.2.1.2. Brazil Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.1.3. Brazil Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
10.2.2. Argentina Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. Argentina Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
10.2.2.2. Argentina Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.2.3. Argentina Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
10.2.3. Rest of South America Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Rest of South America Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
10.2.3.2. Rest of South America Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
10.2.3.3. Rest of South America Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
Chapter 11. Middle East & Africa Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Middle East & Africa Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market Indication and projections, 2017 - 2028 (USD Million)
11.1.2. Middle East & Africa Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
11.1.3. Middle East & Africa Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
11.1.4. Middle East & Africa Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
11.2. Middle East & Africa Psilocybin Assisted Therapy Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. GCC Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. GCC Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
11.2.1.2. GCC Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.1.3. GCC Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
11.2.2. South Africa Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. South Africa Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
11.2.2.2. South Africa Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.2.3. South Africa Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
11.2.3. Rest of Middle East & Africa Psilocybin Assisted Therapy Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Rest of Middle East & Africa Psilocybin Assisted Therapy Market Overview, By Psilocybin Source Type, 2017 - 2028 (USD Million)
11.2.3.2. Rest of Middle East & Africa Psilocybin Assisted Therapy Market Overview, By Indication, 2017 - 2028 (USD Million)
11.2.3.3. Rest of Middle East & Africa Psilocybin Assisted Therapy Market Overview, By End-users, 2017 - 2028 (USD Million)
Chapter 12. Competitive Landscape
12.1. Competitive Environment, 2021
12.2. Strategic Framework
12.2.1. Partnership/Collaborations/Agreement
12.2.2. Expansion
12.2.3. Mergers & Acquisitions
12.2.4. New Product Development
Chapter 13. Key Vendor Analysis
13.1. MindMed
13.1.1. Business Overview
13.1.2. Product Benchmarking
13.1.3. Financial Data
13.1.4. Strategic Overview
13.1.5. Key Developments
13.1.6. SWOT Analysis
13.2. Compass Pathways
13.2.1. Business Overview
13.2.2. Product Benchmarking
13.2.3. Financial Data
13.2.4. Strategic Overview
13.2.5. Key Developments
13.2.6. SWOT Analysis
13.3. ATAI Life Sciences
13.3.1. Business Overview
13.3.2. Product Benchmarking
13.3.3. Financial Data
13.3.4. Strategic Overview
13.3.5. Key Developments
13.3.6. SWOT Analysis
13.4. Field Trip
13.4.1. Business Overview
13.4.2. Product Benchmarking
13.4.3. Financial Data
13.4.4. Strategic Overview
13.4.5. Key Developments
13.4.6. SWOT Analysis
13.5. Eleusis
13.5.1. Business Overview
13.5.2. Product Benchmarking
13.5.3. Financial Data
13.5.4. Strategic Overview
13.5.5. Key Developments
13.5.6. SWOT Analysis
13.6. Numinus Wellness Inc.
13.6.1. Business Overview
13.6.2. Product Benchmarking
13.6.3. Financial Data
13.6.4. Strategic Overview
13.6.5. Key Developments
13.6.6. SWOT Analysis
13.7. Mindbloom
13.7.1. Business Overview
13.7.2. Product Benchmarking
13.7.3. Financial Data
13.7.4. Strategic Overview
13.7.5. Key Developments
13.7.6. SWOT Analysis
13.8. Freedom Biosciences
13.8.1. Business Overview
13.8.2. Product Benchmarking
13.8.3. Financial Data
13.8.4. Strategic Overview
13.8.5. Key Developments
13.8.6. SWOT Analysis
13.9. Natural MedTech
13.9.1. Business Overview
13.9.2. Product Benchmarking
13.9.3. Financial Data
13.9.4. Strategic Overview
13.9.5. Key Developments
13.9.6. SWOT Analysis
13.10. The Enosis Therapeutics
13.10.1. Business Overview
13.10.2. Product Benchmarking
13.10.3. Financial Data
13.10.4. Strategic Overview
13.10.5. Key Developments
13.10.6. SWOT Analysis
13.11. Clairvoyant Therapeutics
13.11.1. Business Overview
13.11.2. Product Benchmarking
13.11.3. Financial Data
13.11.4. Strategic Overview
13.11.5. Key Developments
13.11.6. SWOT Analysis
13.12. Woke Pharmaceuticals
13.12.1. Business Overview
13.12.2. Product Benchmarking
13.12.3. Financial Data
13.12.4. Strategic Overview
13.12.5. Key Developments
13.12.6. SWOT Analysis
13.13. Other Prominent Players
Chapter 14. Future Outlook of the Market
Disclaimer
Published On:Nov-22
Base Year:2021
Historical Data:2019-2020
No of Pages:250
Psilocybin Assisted Therapy Market Growth, Trends ...
RD Code : HP22